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Abstract
Purpose: To identify tissue microRNAs predictive of sunitinib activity in patients with metastatic renal-cell-carcinoma
(MRCC) and to evaluate in vitro their mechanism of action in sunitinib resistance.
Methods: We screened 673 microRNAs using TaqMan Low-density-Arrays (TLDAs) in tumors from MRCC patients with
extreme phenotypes of marked efficacy and resistance to sunitinib, selected from an identification cohort (n = 41). The most
relevant differentially expressed microRNAs were selected using bioinformatics-based target prediction analysis and
quantified by qRT-PCR in tumors from patients presenting similar phenotypes selected from an independent cohort
(n = 101). In vitro experiments were conducted to study the role of miR-942 in sunitinib resistance.
Results: TLDAs identified 64 microRNAs differentially expressed in the identification cohort. Seven candidates were
quantified by qRT-PCR in the independent series. MiR-942 was the most accurate predictor of sunitinib efficacy (p = 0.0074).
High expression of miR-942, miR-628-5p, miR-133a, and miR-484 was significantly associated with decreased time to
progression and overall survival. These microRNAs were also overexpressed in the sunitinib resistant cell line Caki-2 in
comparison with the sensitive cell line. MiR-942 overexpression in Caki-2 up-regulates MMP-9 and VEGF secretion which, in
turn, promote HBMEC endothelial migration and sunitinib resistance.
Conclusions: We identified differentially expressed microRNAs in MRCC patients presenting marked sensitivity or resistance
to sunitinib. MiR-942 was the best predictor of efficacy. We describe a novel paracrine mechanism through which high miR-
942 levels in MRCC cells up-regulates MMP-9 and VEGF secretion to enhance endothelial migration and sunitinib resistance.
Our results support further validation of these miRNA in clinical confirmatory studies.
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Introduction
Several drugs have been developed for metastatic renal-cell
carcinoma (MRCC) during recent years, establishing a complex
scenario in which the choice of the optimal agent for each patient
is cumbersome. Therefore, the development of predictive
biomarkers to maximize clinical benefit and to spare unnecessary
toxicities and costs remains an unmet challenge.
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MicroRNAs (miRNAs) are noncoding single-stranded small
RNAs (,22 nucleotides) that regulate posttranscriptional gene
expression. MiRNAs levels are altered in many human diseases
including cancer, where they can act either as oncogenes or as
tumor-suppressor genes, thus playing a crucial role in tumor
initiation, progression and metastasis. MiRNAs are highly stable
molecules that can be quantified in tissues and body fluids and are
therefore considered a promising platform for the development of
cancer biomarkers [1]. Different miRNA signatures have been
explored for diagnosis, staging and sub-classification of cancer, as
well as for predicting prognosis and treatment efficacy. Several
studies have addressed their implication in renal-cell carcinoma
and recently their importance as potential predictive serum
biomarkers of treatment response has been described [2]
The aim of this study was to identify candidate predictive tumor
miRNAs in MRCC patients treated with sunitinib, one of the most
widely used drugs in this setting, and to further understand their
contribution to the molecular mechanisms of sunitinib resistance.
We employed the methodology of extreme phenotype selection,
which consists of screening potential biomarkers with high-
throughput techniques in the patients that present the most
informative clinical features, in order to increase the probability of
finding molecular factors potentially linked to such phenotypes.
We selected the most significant miRNAs and studied them in an
independent cohort of MRCC patients treated with sunitinib, to
assess their predictive role in this setting. Results were also
investigated in in vitro systems using MRCC and endothelial cells,
as microenvironmental tumor-endothelial cell interactions are
essential for response to sunitinib.
Materials and Methods
Patient selection and study design
Two cohorts of MRCC patients treated with sunitinib were
selected. The screening cohort was obtained from one institution
and included 41 patients. The independent cohort was recruited
from 15 institutions and included 101 patients [3]. Characteristics
of patients selected from both cohorts are shown in Table 1. All
patients had received sunitinib 50 mg daily in a standard four
week treatment, followed by two week rest continuous schedule.
None had received previous therapy either with antiangiogenics or
m-TOR inhibitors. Patients were managed according to standard
clinical practice. Response was evaluated every two cycles using
RECIST criteria. Time to progression (TTP) and overall survival
(OS) were monitored from the start of treatment. The study
protocol was approved by the Ethical Review Board of Clinica
Universidad de Navarra as the Reference Ethics Committee. All
patients signed written informed consent.
We used the methodology of extreme phenotype selection
[4,5,6,7]. This methodology has previously been used to identify
biomarkers of drug related toxicity [8,9] and sunitinib efficacy
[10]. In each cohort we selected two groups of patients with
extreme phenotypes of marked sensitivity or resistance to sunitinib.
The criteria to select sensitive patients were TTP greater than 22
months (twice the time reported in the sunitinib phase III
registration trial [11]) or a partial response greater than 50%.
Patients were categorized as extreme phenotypes of sunitinib
resistance when TTP was#5 months (half the time reported in the
phase III registration trial). To ensure that these patients were
truly resistant to sunitinib, performance status #1 and absence of
comorbidities were required for eligibility.
Taqman Low density array (TLDA) screening
Tumor samples from patients from the screening cohort
presenting extreme phenotypes of sunitinib sensitivity (n = 3) and
resistance (n = 3) were assayed with TLDAs to identify potential
candidate predictive miRNAs. Tissues were formalin-fixed and
paraffin-embedded. Following confirmation of tumor presence by
a pathologist, total RNA from four unstained sections (10 mm) was
extracted with the RecoverAllTM Total Nucleic Acid Isolation Kit
(Ambion). The concentration and quality of total RNA were
determined by analysis of 1 ml of the RNA solution in a NanoDrop
1000 Spectrophotometer (Thermo Scientific). An average of 20 mg
of RNA was obtained.
350 ng of total RNA from each patient was first reverse-
transcribed using a stem-loop RT Megaplex Primer Pool and the
Taqman MicroRNA Reverse Transcription Kit (Applied Biosys-
tems). cDNAs were preamplified with the TaqMan Preamp
Master Mix kit and Megaplex Preamp Primer Human pools.
Expression of 667 human mature miRNAs and six endogenous
controls was profiled using TLDA microfluidic cards A and B
(Applied Biosystems) on a 7900HT Fast real time system.
MammU6 expression was used as endogenous control.
Differentially expressed miRNAs (p,0.05) were selected for
further study after bioinformatic analysis of target prediction data
bases and thorough analysis of bibliography, to select potential
candidates that could be involved in MRCC-related pathways and
response to sunitinib. The following databases were used for target
prediction: TargetScan release 5?1 [12], PicTac [13], PITA
release 6 [14], miranda release sept2008 [15], and microcosm
released 5 [16].
MiRNA quantification in tumor samples by qRT-PCR
Selected miRNAs were quantified by qRT-PCR in tumors from
patients with extreme phenotypes of sunitinib sensitivity (n = 14) or
resistance (n = 6) from the independent series. 20 ng of total RNA
and miRNA-specific primers for the selected miRNAs and for
RNU6B (endogenous control) were used for stem-loop RT,
followed by q-PCR amplification for 40 cycles using miRNA-
specific primers and Taqman PCR master mix, in a 7300Real
Time PCR System (Applied Biosystems). PCR reactions for each
sample were performed in triplicate and expression values were
normalized to RNU6B.
Development of an in vitro MRCC sunitinib-resistant cell
model and analysis of miRNA expression
Caki-2 cells isolated from MRCC cell lines (ATCC, Manassas,
VA, USA) were cultured in McCoy’s 5a Medium modified with L-
Glutamine (Biowhitaker) supplemented with 10% Fetalclone III
(Hyclone) and 1% of Penicillin-Streptomycin (Gibco). A sunitinib-
resistant Caki-2 cell line (SRCaki-2) was generated by continuous
exposure for four months to gradually increasing doses of
sunitinib: From 8 mM to 14 mM (Sutent, LC laboratories). The
initial dose of 8 mM, corresponding to the LD50, was selected from
a previous MTT assay, where sunitinib cytotoxicity was tested
with doses ranging from 0.001 mM to 20 mM for 72 hours.
Total RNA from Caki-2 and SRCaki-2 cells was obtained by
the Trizol extraction method (Invitrogen) and expression of the
selected miRNAs was studied by qRT-PCR. Expression results
were normalized to RNU6B levels.
miR-942 overexpression in MRCC Caki-2 cell line
Pre-miR-942 and pre-miR Negative Control (5 nmol, Ambion)
were transfected into parental Caki-2 cells grown in six-well plates
(seeded 24 hours before at 26105 cells/well) with Lipofectamine
microRNA Predictive of Sunitinib Activity
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2000 (Invitrogen). Total RNA was extracted after 72 hours and
transfection efficiency was verified by qRT-PCR. Sunitinib
sensitivity of transfected cells was studied by MTT assay following
doses and protocol described before.
Gene expression by qRT-PCR
Expression of sunitinib-targeted tyrosine kinase receptors,
Platelet-derived Growth Factor Receptors (PDGFRa and b),
Vascular Endothelial Growth Factor Receptors (VEGF-R 1, 2, 3),
c-Kit, FLT3 and levels of the cytokines matrix metalloproteinase-9
(MMP-9), tumour necrosis factor-a (TNF-a) and interleukin-8 (IL-
8), were measured by qRT-PCR.
Western blot and zymogram
After 48 h incubation, serum-free cell supernatants and extracts
from transfected cells were recovered to perform subsequent
VEGF and MMP-9 western blot analysis (S1 Text). Gelatin
zymography (Invitrogen) of secreted proteins was analysed to
check MMP-9 gelatinolytic activity (S2 Text).
Co-culture and cell migration assays
HBMEC endothelial cells kindly donated by Dr. Lecanda
(Laboratory of Cell Adhesion and Metastasis, CIMA) were grown
on 0.2% gelatine-coated plates in EBM-2 medium supplemented
with 5%FBS. MiR-942/Caki-2 cells and HBMEC were co-
cultured in 0.4 mm pore size 6-well Boyden chambers. HBMEC
(1.56105 cell/well) were plated at the bottom of the plates in
EBM-2 medium. After 2 h, 86104 miR-942-overexpressing Caki-
2 cells or control cells (mock-transfected) were seeded in McCoy’s
5a Medium in the inserts. Co-culture was incubated for 72 hours
and HBMEC cells were then harvested to perform MTT (with
sunitinib doses up to 35 mM), western blot for p-VEGFR2, total
Table 1. Patient characteristics.
Characteristic Screening cohort Independent cohort
Sensitive Resistant Sensitive Resistant
N = 3 N = 3 N = 14 N = 6
(%) (%) (%) (%)
Sex
Male 2 (67) 1 (33) 12 (86) 2 (33)
Female 1 (33) 2 (67) 2 (14) 4 (67)
Age
Median 52 47 59 60
Range (47–59) (39–61) (40–70) (47–81)
Performance status
0 3 (100) 2 (67) 6 (43) 2 (33)
1 - 1 (33) 7 (50) 4 (67)
2 - - 1 (7) -
Tumor histology
Clear-cell carcinoma 3 (100) 3 (100) 14 (100) 6 (100)
MSKCC prognostic group
Good 3 (100) - 6 (43) -
Intermediate - 2 (67) 5 (36) 4 (67)
Poor - 1 (33) - 1 (16)
Unavailable - - 3 (21) 1 (16)
Number of metastatic sites
Median 2 4 2 2
Range (2–3) (2–5) (1–4) (1–3)
Sites of metastasis
Lymph nodes 2 (67) 3 (100) 6 (43) 3 (50)
Lung 3 (100) 2 (67) 10 (71) 6 (100)
Bone - 3 (100) 4 (29) 1 (16)
Liver - 1 (33) - 1 (16)
Kidney 1 (33) - 1 (7) -
Response to sunitinib
Partial response 3 (100) - 11 (79) -
Stable disease - - 3 (21) -
Progression - 3 (100) - 6 (100)
Median time to progression (months) 32 2 31 3
doi:10.1371/journal.pone.0086263.t001
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VEGFR2, p-p44/p42 MAPK (Erk1/2) and total Erk1/2 (S3
Text), and for migration assays.
Migration was performed in 24 well Boyden chambers.
HBMEC (56104 cells) were seeded in the chamber in a final
volume of 150 ml in serum free medium. The lower compartment
was filled with 450 ml of 5% serum containing EBM-2 medium to
chemoattract the cells. 48 h later, cells from the insert were
removed with a swab and cells that migrated to the lower
compartment were fixed with 4% formalin, stained with crystal
violet and counted with a Leica DMIL LED microscopy.
Statistical methods
Statistical differences in normalized miRNA expression between
extreme phenoytpes were examined with the Mann-Whitney U-
test for unpaired non-parametric variables and the Student’s t-test
for unpaired data for parametric variables. Normality was tested
with the Shapiro-Wilks Test. Data were analysed with SPSS
software, version 15.0. P-values,0.05 were considered statistically
significant. Survival variables were studied with the Kaplan-Meier
test and curves were compared with the Log-rank test. The study
was designed and the results reported following REMARK
guidelines.
TLDAs data were analysed with R/Bioconductor [17],
performing a filtering process to eliminate the miRNAs not
detected in the experiment, followed by normalization and
LIMMA statistical analysis [18]. A p-value threshold of 0.05 was
established to select differentially expressed miRNAs.
A machine learning algorithm based on logistic regression was
applied to classify patients and to identify the optimal separating
miRNAs between extreme phenotypes. The performance of the
classifiers was evaluated using Receiver Operator Characteristics
Curve (ROC) analysis.
Results
Screening of miRNAs with TLDAs
TLDA profiling of 673 miRNA in tumors from six patients
belonging to the screening cohort presenting extreme phenotypes
of marked sunitinib efficacy (n = 3: 7.3%) or resistance (n = 3:
7.3%) identified 64 miRNAs differentially expressed (p,0.05)
between both groups (data deposited in NCBI’s Gene Expression
Omnibus and accessible through GEO Series accession number
GSE37766). Seven candidates (miR-133a, miR-628-5p, miR-942,
miR-484, miR-146a-5p, miR-374a and miR-486-5p) were select-
ed for further study based on these criteria: Differential expression
obtained from the TLDA analysis; bioinformatic-based target
prediction databases combined with bibliographic search to
identify microRNAs related to MRCC development or sunitinib-
targeted pathways.
Assessment of miRNAs by qRT-PCR in the independent
series
Selected miRNAs were studied by qRT-PCR in tumors from
patients with extreme phenotypes of sunitinib response (n = 14,
11.9%) and resistance (n = 6, 5.1%) belonging to the independent
series. Increased levels of miR-942, miR-133a, miR-628-5p and
miR-484 were observed in resistant phenotypes as compared with
sensitive phenotypes (Figure 1), achieving statistical significance for
miR-942 (p= 0.0074). The remaining miRNAs showed borderline
significant p-values (Figure 1). The tendency of the expression of
some miRNAs was opposite to that found in the TLDAs. No
differences were found in the other miRNAs (Figure S1A).
Prediction of efficacy was superior for miR-942 alone [Area
Under the ROC curve (AUROCC=0.798, sensitivity (S) = 92%,
specificity (Sp) = 50%] than for the 4-miRNA combination
(AUROCC=0.619, S= 85%, Sp= 50%).
High expression of miR-133a, miR-628-5p, miR-942 and miR-
484 was significantly associated with reduced TTP and OS
(Figure 2 and table S1). No correlation was found between
expression of the other miRNAs and survival variables (data not
shown).
miRNAs expression in sunitinib-resistant Caki-2 cells
We established a sunitinib-resistant Caki-2 cell line (SRCaki-2)
to validate our results. 90% of SRCaki-2 cells were alive after
72 hours of sunitinib exposure at 12 mM dose, as compared with
only 12% of cells in the sensitive parental Caki-2 (Figure S2).
We quantified levels of the 7 selected miRNAs by qRT-PCR in
sensitive and resistant cells. Overexpression of miR-133a
(p = 0.006), miR-484 (p = 0.0152) and miR-942 (p = 0.05) and
downregulation of miR-486-5p (p = 0.017) was found in resistant
cells in comparison with sensitive cells (Figure 3 and S1B), as was
the case for patients showing resistance. No statistically significant
differences were observed for the other three miRNAs, although
the expression trend was similar to that observed in patients
(Figure S1B).
miR-942 overexpression in Caki-2 cells promotes MMP-9
and VEGF secretion
We then studied the mechanism by which miR-942 could
contribute to sunitinib resistance. With this aim, pre-miR-942 was
Figure 1. Tumor microRNA expression in MRCC patients with extreme phenotypes treated with sunitinib from the independent
cohort., (sunitinib sensitive, n = 14 and sunitinib resistant, n = 6). MiR-942, miR-628-5p, miR-133a and miR-484 were overexpressed in sunitinib
resistant patients. MiR-942 significantly discriminated between both patients groups. MiRNA levels are represented as 22DCt mean 6 SEM. MiRNA
expression was normalized against RNU6B. R = responders. NR=non responders.
doi:10.1371/journal.pone.0086263.g001
microRNA Predictive of Sunitinib Activity
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transfected to Caki-2 cells to induce miR-942 overexpression.
MTT assays showed that the increase of miR-942 did not modify
sunitinib cytotoxicity on Caki-2-transfected cells (Figure S2). We
next evaluated the expression of PDGFR (a predicted target for
this microRNA), but found no expression in these cells. Moreover,
no significant expression of the other sunitinib-targeted receptors
was observed (results not shown). These findings suggested that
resistance to sunitinib mediated by miR-942 upregulation might
be related to a paracrine effect. To try to identify alternative
pathways regulated by miR-942, we studied the expression of pro-
angiogenic cytokines that have been previously described to confer
resistance to sunitinib in cancer patients, including MMP-9, TNF-
a [10] and IL-8 [19]. mRNA levels of MMP-9 were significantly
increased (p = 0.0005) in miR-942-overexpressing cells compared
to controls (Figure 4A), whereas no differences were observed for
TNF-a and IL-8 (data not shown).
Confirmation of this result by Western blot is shown in
Figure 4B: miR-942/Caki-2 cells secreted more MMP-9 as well
as its downstream regulated gene VEGF than miR-Neg/Caki-2
cells. Supernatants from miR-942/Caki-2 cells were enriched in
both pro-MMP-9 (92 KDa) and activated-MMP-9 (86 KDa) and
glycosylated/non-glycosylated VEGF121 (15 KDa) and VEGF165
(23 KDa), as well as the non-glycosilated VEGF165/glycosilated
VEGF121 (18 KDa). In addition, proteinase activity of soluble
MMP-9 evaluated by gelatin-zymography demonstrated a stron-
ger band (86 KDa) for miR-942/Caki-2 cells than that of miR-
Neg/Caki-2 cells (Figure 4B). All these results show that miR-942
induces secretion of both active MMP-9 and VEGF.
To assess whether this regulatory system would also be
functional in the Caki-2 resistant cells that we generated,
expression of MMP-9 and VEGF in SRCaki-2 was checked.
Levels of miR-942 were slightly increased (1.5 fold) in these cells,
and levels of MMP-9 and VEGF were similar to parental control
(data not shown). This result suggests that SRCaki-2 cells, which
were generated by continuous exposure to the drug, may have
acquired resistance through mechanisms different to miR-942
upregulation.
Paracrine regulation of miR-942-mediated MMP-9 and
VEGF secretion by tumor cells on endothelial cells
We next investigated whether high levels of secreted active
MMP-9 and VEGF by miR-942/Caki-2 cells would have
functional effects on endothelial cells. HBMEC migration ability
was significantly increased (p = 0.047) 72 hours after co-culture
with miR-942/Caki-2 (Figure 5A) in comparison to miR-Neg/
Caki-2 cells. Increased levels of phosphorylated VEGFR2
(230 KDa) and phosphorylated p44/42 MAPK (Erk 1/2) (42–
44 KDa) was observed in HBMEC after co-culture with miR-
942/Caki-2 (Figure 5B). These findings indicate that miR-942
overexpression by MRCC cells promotes migration of endothelial
cells through MMP-9 and VEGF overexpression.
Moreover, HBMEC co-cultured with miR-942/Caki-2 cells
were less sensitive to the cytotoxic effect of sunitinib
(LD50.35 mM) than those co-cultured with miR-Neg/Caki-2
cells (LD50 13.5 mM) (Figure 5C). Based on our results, we propose
a model that could explain how MRCC tumor cells with high
miR-942 expression may act through paracrine mechanisms to
enhance angiogenesis and resistance to sunitinib (Figure 6).
Discussion
MiRNAs play a relevant role in the pathogenesis and the
natural history of MRCC. Differential expression of miRNAs in
MRCC compared to normal kidney has been described by
previous studies [20] and miRNA signatures can accurately classify
different histological subtypes of MRCC [21,22]. Moreover,
miRNAs have been related to the risk of developing early
metastasis following nephrectomy [23] and with OS and TTP
[24,25]. However, there is very limited information about the role
of miRNAs as predictive biomarkers of treatment efficacy in
MRCC.
miRNAs posses both advantages and disadvantages as potential
biomarkers. Minute amounts of paraffin-embedded tissue can be
used to measure a large number of miRNAs, but the lack of
standardization in methods and cut-off values may hinder their
potential as biomarkers. Despite these potential problems, an
increasing number of studies are exploring microRNAs as
Figure 2. Association between miRNA expression and TTP and OS. TTP and OS were significantly reduced in MRCC patients treated with
sunitinib that had (A) miR-942 expression over the mean; (B) miR-628-5p levels over the mean; (C) miR-133a levels over p75; (D) and miR-484
expression over the mean.
doi:10.1371/journal.pone.0086263.g002
Figure 3. MicroRNA levels in the sunitinib-resistant Caki-2 cell line (SRCaki-2) and its sunitinib-sensitive counterpart. MiR-942, miR-
133a and miR-484 were significantly overexpressed in resistant cells. MiRNAs expression is showed as 22DCt mean6 SEM. Expression was normalized
against RNU6B.
doi:10.1371/journal.pone.0086263.g003
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predictive biomarkers in different cancer types. miR-26 was
reported to predict interferon-a efficacy in hepatocellular carci-
noma [26]. High tumor levels of miR-92a-2* are associated with
chemoresistance and decreased survival in NSCLC and the miR-
200 family might constitute a predictive biomarker of paclitaxel-
based therapy in ovarian carcinoma [27]. Gamez-Pozo et al. have
recently described that expression of particular miRNA signatures
in peripheral blood predicts sunitinib activity in MRCC [2].
We have identified candidate tumor miRNAs predictive of
sunitinib efficacy in MRCC through screening of 673 miRNAs
using TLDAs. We selected MRCC patients with extreme
phenotypes of marked efficacy or primary resistance to sunitinib.
By focusing on these patient subsets, we increased the probability
of finding clinically relevant results and reduced the number of
screened patients and the costs of using expensive high-throughput
platforms. The rationale behind the use of a high-throughput
technique is to increase the chance of finding relevant predictive
factors by exploring a large number of potential candidates. We
found 64 miRNAs differentially expressed between both groups
and seven of these were selected for further analysis based on
results obtained from bioinformatic-based target prediction
databases and by their relationship with MRCC development
and sunitinib-targeted pathways.
qRT-PCR in an independent cohort showed that miR-942,
miR-133a, miR-628-5p, and miR-484 levels were increased in
tumors from sunitinib resistant patients. High expression of these
miRNAs was significantly associated with OS and TTP. ROC
analysis showed that miR-942 alone could accurately classify the
selected extreme phenotypes and thus, warrants further study as a
predictive biomarker of sunitinib activity. Interestingly, our
findings in patients were replicated in a sunitinib-resistant Caki-2
cell line developed for this purpose.
Bioinformatic databases predict that, among other genes, miR-
942 targets PDGFR. However, both MRCC Caki-2 and
endothelial HBMEC [28] cells lack PDGFR; moreover, all other
sunitinib-targeted receptors were not expressed (or were almost
undetectable) in Caki-2 cells as well. Therefore, the mechanisms of
resistance cannot be related in this experimental system with a
miR-942-mediated decrease in PDGFR levels, which would lead
to sunitinib resistance. In addition, we found that sensitivity of
Caki-2 cells to sunitinib was not modified by miR-942 overex-
pression.
In search for a possible alternative mechanism, we quantified
levels of angiogenic factors that have been previously reported to
be associated with sunitinib in patients, such as MMP-9, TNF-a
and IL-8. Overexpression of miR-942 in Caki-2 cells caused a
significant upregulation of MMP-9 (and its downstream angio-
genic factor VEGF) in these cells. Co-culture experiments using
Caki-2 and HBMEC cells demonstrated the existence of a
paracrine loop activated by miR-942 that resulted in activation
of VEGFR-mediated signalling cascades, endothelial cell migra-
tion and resistance to sunitinib. It is known that MMP-9 is highly
produced and secreted by malignant cells, and that its overex-
pression correlates with poor prognosis and survival in several
cancer types [29]. This metalloproteinase regulates VEGF
bioavailability and release, leading to angiogenesis and metastasis
Figure 4. MMP-9 increases in miR-942/Caki-2 cell line. (A) MMP-9 mRNA levels in miR-942/Caki-2 cells were significantly increased in
comparison to miR-Neg/Caki-2. Data are represented as 22(DDCt) using GAPDH as housekeeping. (B) Secreted MMP-9 (both the 92 KDa proform and
the active form 86 KDa) and VEGF isoforms (VEGF165G/23 KDa, VEGF165NG/VEGF121G/18 KDa, VEGF121NG/15 KDa) levels are higher in miR-942/Caki-2
than in the negative control. Proteolytic activity of secreted MMP-9 was proven by gelatin-zymography.
doi:10.1371/journal.pone.0086263.g004
microRNA Predictive of Sunitinib Activity
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[30]. Jadhav et al showed that inhibition of MMP-9 results in a
reduction of in vitro endothelial cell invasion and tube formation,
thus demonstrating that MMP-9 plays a key role in endothelial cell
networking and angiogenesis [31].
We then provide in the present study first evidence of a novel
paracrine mechanism that involves the activation of miR-942/
MMP-9/VEGF axis in cancer cells to promote endothelial cell
migration and resistance to sunitinib. In line with our findings in
vitro, we demonstrated in a previous study that high circulating
MMP-9 levels are significantly associated with lack of response to
sunitinib and shorter TTP and OS in MRCC patients [10]. Taken
together, these data strongly suggest that MMP-9 can be a key
factor for sunitinib resistance.
The question about how increased levels of miR-942 lead to
MMP-9 and VEGF upregulation still remains to be solved. Our
preliminary results (unpublished observations) using microarray
analysis combined with identification of potential miR-942 targets
suggest a downregulation of several genes of the Fanconi Anemia/
BRCA pathway [32]. Transcriptional repression of this pathway
has been shown to induce MMP-9/VEGF levels [33,34], which
Figure 5. Functional effects of secreted MMP-9 and VEGF on endothelial cells. (A) Migration of HBMEC was significantly increased after co-
culture with miR-942/Caki-2 (*: p,0.05), as compared with co-culture with miR-Neg/Caki-2 cells. (B) HBMEC became less sensitive to sunitinib activity
after co-culture with miR-942/Caki-2 (LD50.35 mM) in comparison to HBMEC co-cultured with miR-Neg/Caki-2 cells (LD50 13.5 mM). (C)
Phosphorylation of VEGFR2 and p44/42 MAPK (Erk1/2) proteins was increased in HBMEC co-cultured with miR-942/Caki-2, as compared to the co-
culture with miR-Neg/Caki-2 cells.
doi:10.1371/journal.pone.0086263.g005
Figure 6. Proposed mechanism for the miR-942-mediated
MMP-9/VEGF paracrine regulation of cancer cells and endo-
thelial cells.
doi:10.1371/journal.pone.0086263.g006
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may offer a possible mechanistic explanation about miR-942
effects. However, this unexplored possibility needs to be addressed
in future work.
Our study has some limitations. Apart from the lack of
standardization (as indicated), the strategy of extreme phenotype
selection, while potentially useful, also requires further develop-
ment, e.g: precise definition of what constitutes an extreme
phenotype, comparability between different studies, optimal
calculation of sample sizes for the screening and validation
cohorts, and extrapolation of the findings in extreme phenotypes
to the general population. Nevertheless, our strategy has success-
fully led us to the identification of novel potential predictive factors
of sunitinib activity.
In conclusion, we have identified a set of four tumor miRNAs
with predictive potential of sunitinib efficacy in MRCC, from
which miR-942 is the most promising candidate. We have also
demonstrated that high levels of miR-942 in tumor MRCC cells
upregulates both MMP-9 and VEGF to induce endothelial cell
migration and resistance to sunitinib. This study also confirms that
extreme phenotype selection in combination with high-throughput
analysis is a valid strategy to identify candidate predictive
biomarkers in cancer research.
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